NEW YORK (GenomeWeb News) – Entelos said today that Eli Lilly has purchased a perpetual license to its DrugMatrix toxicogenomics database.
Under the terms of the agreement, Lilly will make a one-time payment to Entelos for a perpetual license to the database and customized report services from the company’s ToxFx business, with the option for continued support.
Financial terms were not disclosed.
Entelos, a biosimulation firm that develops "virtual humans" to help predict drug response, picked up the DrugMatrix database in its acquisition of Iconix last August.
The database is a reference set of gene expression profiles for benchmark drugs and compounds that are linked to pharmacology, toxicology, and clinical pathology measurements. It currently includes profiles from more than 630 different compounds.